In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Surface Oncology (SURF – Research Report), with a price target of $18.00. The company’s shares closed last Friday at $7.95.
Surface Oncology has an analyst consensus of Strong Buy, with a price target consensus of $16.25.
Based on Surface Oncology’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $87.57 million and net profit of $67.35 million. In comparison, last year the company earned revenue of $439K and had a GAAP net loss of $15.95 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Surface Oncology, Inc. is a clinical-stage immuno-oncology company, which focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.